An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer's Disease: A Randomized Controlled Trial.
Activities of Daily Living
Aged
Aged, 80 and over
Alzheimer Disease
/ drug therapy
Antipsychotic Agents
/ therapeutic use
Blood Pressure
Environment
Female
Gardening
Gardens
Humans
Hydrocortisone
/ analysis
Male
Mental Status and Dementia Tests
Neuropsychological Tests
Quetiapine Fumarate
/ therapeutic use
Single-Blind Method
Treatment Outcome
Alzheimer’s disease
behavioral symptoms
cortisol
gardens
non-pharmacological treatment
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
20
8
2019
medline:
6
11
2020
entrez:
20
8
2019
Statut:
ppublish
Résumé
Behavioral and psychological symptoms of dementia (BPSD) affect 60-90% of patients with Alzheimer's disease (AD). To determine if environmental therapy is an effective strategy to reduce BPSD, we tested 163 patients with AD with Neuropsychiatric Inventory (NPI) before and after 6 months of an indoor therapeutic garden (TG) or standard environment. A single-blind randomized controlled trial on AD patients with BPSD. Participants were randomized to an indoor TG (N = 82), or standard environment (control, N = 81) for 6 months. change in the NPI score from baseline (T0) to end of treatment (T1). change in use of quetiapine, cognition, activities of daily living, salivary cortisol, blood pressure from T0 to T1. NPI score significantly ameliorated (TG versus control: -31.8 points), quetiapine dosage (-150 mg), blood pressure (-2.6 mm Hg), and salivary cortisol (-6.4 to -2.1 Nmol/l) were significantly reduced, the Mini-Mental State Examination significantly improved (1.8 points) in the TG versus control arm at T1 (p < 0.001). No adverse events were reported. The indoor TG seems safe and may reduce BPSD, medication intake, and cortisol levels in AD.
Sections du résumé
BACKGROUND
Behavioral and psychological symptoms of dementia (BPSD) affect 60-90% of patients with Alzheimer's disease (AD).
OBJECTIVE
To determine if environmental therapy is an effective strategy to reduce BPSD, we tested 163 patients with AD with Neuropsychiatric Inventory (NPI) before and after 6 months of an indoor therapeutic garden (TG) or standard environment.
METHODS
A single-blind randomized controlled trial on AD patients with BPSD. Participants were randomized to an indoor TG (N = 82), or standard environment (control, N = 81) for 6 months.
PRIMARY OUTCOME
change in the NPI score from baseline (T0) to end of treatment (T1).
SECONDARY OUTCOMES
change in use of quetiapine, cognition, activities of daily living, salivary cortisol, blood pressure from T0 to T1.
RESULTS
NPI score significantly ameliorated (TG versus control: -31.8 points), quetiapine dosage (-150 mg), blood pressure (-2.6 mm Hg), and salivary cortisol (-6.4 to -2.1 Nmol/l) were significantly reduced, the Mini-Mental State Examination significantly improved (1.8 points) in the TG versus control arm at T1 (p < 0.001). No adverse events were reported.
CONCLUSION
The indoor TG seems safe and may reduce BPSD, medication intake, and cortisol levels in AD.
Identifiants
pubmed: 31424399
pii: JAD190394
doi: 10.3233/JAD-190394
doi:
Substances chimiques
Antipsychotic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM